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p62sential cellular function that, when dysregulated or impaired, can lead to a wide
variety of disease states. The two major intracellular protein degradation systems are the ubiquitin-
proteasome system (UPS) and autophagy, a catabolic process that involves delivery of cellular components to
the lysosome for degradation. While the UPS has garnered much attention as it relates to neurodegenerative
disease, important links between autophagy and neurodegeneration have also become evident. Furthermore,
recent studies have revealed interaction between the UPS and autophagy, suggesting a coordinated and
complementary relationship between these degradation systems that becomes critical in times of cellular
stress. Here we describe autophagy and review evidence implicating this system as an important player in
the pathogenesis of neurodegenerative disease. We discuss the role of autophagy in neurodegeneration and
review its neuroprotective functions as revealed by experimental manipulation in disease models. Finally, we
explore potential parallels and connections between autophagy and the UPS, highlighting their collaborative
roles in protecting against neurodegenerative disease.
© 2008 Elsevier B.V. All rights reserved.1. A precarious balanceThe energy expenditure needed to produce protein is substantial;
thus, the degradation of these macromolecules comes at a high cost.
Nevertheless, protein turnover is essential for removing defective
proteins and for contributing to the pool of amino acids required for
continued protein synthesis, particularly in times of limited nutrient
availability. Furthermore, many essential cellular functions – including
cell division, transcription, and signal transduction – are regulated by
ﬂuctuation in protein levels accomplished by altering the balance of
protein synthesis and degradation. The role of protein catabolism in
protecting cells from defective, misfolded proteins has been the
subject of increased attention as its relevance to human disease has
become apparent. A substantial fraction of newly synthesized proteins
are translated incorrectly or fold incorrectly due to errors in synthesis
or genetic mutations [1–4]. Oxidative or nitrosylative damage adds to
the burden of defective proteins. Efﬁcient degradation of these
proteins is essential, as cells cannot risk the long-term accumulation
of proteins that engage in aberrant protein-protein interactions, form
insoluble aggregates, or acquire other toxic properties. Considering
the importance of protein catabolism in maintaining cell homeostasis,
it is not surprising that dysregulation of protein turnover is associated
with myriad disease states such as cancer and neurodegeneration [5].ildren's Research Hospital, 262
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l rights reserved.Two major pathways accomplish regulated protein catabolism: the
ubiquitin-proteasome system (UPS) and the autophagy-lysosomal
system. The UPS serves as the primary route for degradation for
thousands of short-lived proteins and provides the exquisite speciﬁcity
and temporal control needed for ﬁne-tuning the steady-state levels of
many regulatoryproteins [6]. UPS-mediated catabolism is also essential
to maintain amino acid pools in acute starvation and contributes
signiﬁcantly to the degradation of defective proteins [1,2,7]. Autophagy,
by contrast, is primarily responsible for degrading long-lived proteins
and maintaining amino acid pools in the setting of chronic starvation,
although its contribution to the degradation of defective proteins may
equal that of theUPS. Though it has received less attention than theUPS
historically, breakthroughs in themolecular genetics of autophagyhave
led to a renaissance of interest in this catabolic pathway and has
revealed many surprising insights about its regulation, function, and
contribution to protein degradation, in both normal and disease states.
This review will (1) highlight the parallels between the UPS and
autophagy in their roles and regulation, (2) explore the role of
autophagy in neurodegeneration, noting parallels with the UPS, and
(3) discuss emerging evidence of a functional relationship between the
UPS and autophagy and its relevance to neurodegeneration.
2. The basics: Roles and regulation
“Autophagy”, literally “self-eating”, describes a catabolic process in
which cell constituents such as organelles and proteins are delivered to
the lysosomal compartment for degradation. Autophagy is an evolu-
tionarily conserved process whose primary task in lower organisms is
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nutrient availability [8]. This role in recycling is complementary to that
of the UPS, which degrades proteins to generate oligopeptides that are
subsequently degraded into amino acids while replenishing the cell's
supply of free ubiquitin. Recent advances have demonstrated that
autophagy also serves a surprisingly diverse array of additional
functions, including organelle clearance, antigenpresentation, elimina-
tionofmicrobes, aswell as regulationof development andcell death [9].
Traditionally, autophagy has been considered a less selective degrada-
tive pathway than the UPS and is frequently illustrated as the
engulfment of large portions of cytoplasm (including nearby cytosolic
bystanders) and delivery of the contents to the lysosome in bulk. This
view of autophagy as a crude, nonselective form of catabolism has been
challenged by the appreciation of specialized forms of autophagy that
are distinguished by the identity of the substrates and the route by
which these substrates reach the lysosomal compartment (Fig. 1).
Microautophagy consists of direct engulfment of small volumes of
cytosol by lysosomes [10], whereas chaperone-mediated autophagy
(CMA) involves selective, receptor-mediated translocation of proteins
into the lysosomal lumen [11]. These processes are distinguished from
macroautophagy, in which an isolation membrane expands to engulf a
portion of the cell, eventually fusing to form a new autophagic vacuole
that subsequently fuses with a lysosome [12]. Evenwithin the category
of macroautophagy, there appears to be capability for selectivity, as
autophagic processes have been observed that appear to be speciﬁc for
mitochondria (mitophagy), portions of the nucleus (nucleophagy),
peroxisomes (pexophagy), endoplasmic reticulum (reticulophagy),
microorganisms (xenophagy), ribosomes (ribophagy) or protein aggre-
gates (aggrephagy) (reviewed in [5]).
While the molecular regulation of microautophagy remains
obscure, there has been substantial insight into the regulation of
CMA and macroautophagy. CMA is a process in which proteins
harboring a pentapeptide motif related to the sequence KFERQ are
speciﬁcally recognized by a cytosolic chaperone, the heat shockFig. 1. The UPS and the autophagy-lysosomal systems are the two main protein degradatio
considered to be substrates for the UPS, which feeds unfolded proteins through the barrel of t
some ubiquitinated substrates can also be degraded via the autophagy-lysosomal system.
engulfed and delivered to the lysosome in bulk, (2) microautophagy, in which small volume
(CMA), in which soluble substrates associated with a speciﬁc chaperone complex are trans
involves a series of maturation steps: ﬁrst, a portion of cytoplasm is surrounded by an
autophagosome, which in mammals fuses with late endosomes and multivesicular bodi
autolysosome, in which cytosolic cargo is degraded by lysosomal hydrolases. LC3-II is a pr
provides a histological marker of autophagic vacuoles. Adapted from [20].cognate protein of 70 kDa (hsc70). The substrate-chaperone complex
is then targeted to the lysosome by binding to lysosome-associated
membrane protein 2A (LAMP-2A) which carries out receptor-
mediated translocation of the substrate into the lysosome for
degradation [11,13]. Up to 30% of all cytosolic proteins harbor the
CMA recognition motif and are potentially subject to degradation by
this catabolic pathway during long-term nutrient deprivation [11,14].
While it remains unclear how substrates are speciﬁcally marked
for degradation by macroautophagy (hereafter referred to as auto-
phagy), the identiﬁcation of a family of autophagy-related (Atg) genes
in yeast and their homologues in higher organisms has permitted
minute dissection of the general process by which autophagy engulfs
and degrades its targets. The initial step in autophagy involves
expansion of a membranous structure called the “isolation mem-
brane” or “phagophore” that engulfs a portion of the cell; the
membrane eventually fuses to form a new double-membraned
structure known as an autophagosome (Fig. 1). The process of
autophagy is controlled by parallel activation cascades that involve
ubiquitin-like (UBL) protein modiﬁcation, strikingly similar to the
activation cascade that regulates the UPS (Fig. 2a). In the ﬁrst arm of
the Atg conjugation system, phagophore membrane elongation is
triggered through the sequential action of an E1-like protein (Atg7)
and an E2-like protein (Atg10) leading to an isopeptide linkage
between the C-terminal glycine in the UBL protein Atg12 and a lysine
residue of Atg5 (Fig. 2b). These Atg12-Atg5 conjugates are further
cross-linked to Atg16 to form a large (∼350 kDa) multimeric complex,
which has been thought to act as a structural support for membrane
expansion [15]. More recent work has demonstrated that the Atg12-
Atg5 conjugate can function as an E3-like enzyme in the second arm of
the Atg conjugation cascade to promote lipidation of Atg8 [16]. In a
second arm of the Atg conjugation system, Atg4 cleaves the UBL
protein Atg8 to promote interactionwith Atg7. Atg8 is then conjugated
with the phospholipid phosphotidylethanolamine (PE) by the
concerted action of the E2-like Atg3 and the E3-like Atg12-Atg5n systems in the cell. Proteins that are tagged with polyubiquitin chains are generally
he 26S proteasome and generates small digested peptides. Recent evidence suggests that
This system is comprised of (1) macroautophagy, in which cytosolic components are
s of cytosol are directly engulfed by lysosomes, and (3) chaperone-mediated autophagy
located into the lysosome through the LAMP-2A lysosomal receptor. Macroautophagy
expanding isolation membrane or phagophore. The phagophore seals to form an
es to form an amphisome. The amphisome then fuses with a lysosome to form an
otein that associates with the inner and outer surfaces of autophagic membranes and
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conjugation, in contrast to the classical E3 protein-protein conjugation
of the UPS. As PE is a component of the autophagosomal membrane,
the lipidation reaction results in studding of the inner and outer
membranes of autophagosomes with Atg8 (Fig. 2c).
Once formed, new autophagosomes move through a stepwise
maturation process that culminates with fusion to a lysosome
permitting degradation of the lumenal contents. In mammals,
autophagosomes ﬁrst fuse with endosomes and multivesicular bodies
to form amphisomes, which subsequently fuse with lysosomes to
create degradative vacuoles termed autolysosomes [17]. Autophago-
somes and autolysosomes can be distinguished morphologically, as
autophagosomes contain contents with densities similar to cytosol,
while autolysosomes appear as electron-dense material with a hollow
rim beneath the limiting membrane. However, because of occasional
ambiguity in distinguishing autophagosomes, amphisomes, and
autolysosomes morphologically, the term “autophagic vacuole”
frequently appears in the literature to refer to all three structures.
Four metazoan homologs of Atg8 have been identiﬁed: MAP-LC3
(microtubule-associated protein light chain 3), GABARAP (γ-amino-
butyric-acid-type-A-receptor-associated protein), GATE-16 (Golgi-
associated ATPase enhancer of 16 kDa), and Atg8L, although GABARAP,
GATE-16, and Atg8L have not been extensively characterized. While
GABARAP and GATE-16 may also be conjugated to PE in experimental
systems, at present MAP-LC3 (typically abbreviated LC3) is the only
protein that is known to remain associated with the autophagosome
in higher eukaryotes. Pro-LC3 is cleaved co-translationally to create a
form of LC3 denoted “LC3-I”. LC3-I becomes conjugated to PE to form
“LC3-II” and thereby covalently associates with the phagophore.
Consequently, the generation and turnover of LC3-II is used as an
index of autophagy induction and/or ﬂux [18]. LC3-II staining is also
used as a primary histological marker of autophagosomes. Because
LC3-II remains on the inner membrane of autophagosomes until
lysosomal enzymes degrade it, increased steady-state levels of LC3-IIFig. 2. Assembly and elongation of autophagic membranes are accomplished via sequential ac
protein (UBL) such as ubiquitin, Atg12, or Atg8. The UBL is then transferred to an E2 conjugati
UBL and its target. (a) In the UPS, ubiquitination of substrates is accomplished by an E1-acti
conjugation pathway, Atg12 associates with the E1-like Atg7, is transferred to the E2-like Atg
pathway. (c) In the second arm of the Atg conjugation pathway, Atg8 associates with the E1-lik
the Atg12-Atg5 complex. Adapted from [101] with permission.may be due to induction of autophagosome formation, a blockade in
their maturation, or both. Distinguishing between these possibilities
for experimental purposes is readily accomplished with the use of
chemical inhibitors of maturation [18].
3. A role for autophagy in neurodegeneration
Many neurodegenerative diseases are characterized by accumula-
tion of misfolded protein deposits in affected brain regions, suggesting
a failure in the cell's degradative capacity [19]. Neurons, as highly
metabolically active, post-mitotic cells, are especially vulnerable to the
accumulation of defective proteins, and this may account for the
frequency with which conformational diseases affect the nervous
system. In most cases, these proteinaceous deposits are composed of
ubiquitin conjugates, suggesting a failure in the clearance of proteins
targeted for proteasomal degradation. Indeed, experimental evidence
indicates that neurodegeneration is frequently associated with
impaired UPS function, although whether this is a cause or
consequence of neurodegeneration is a contested issue, as is reviewed
elsewhere in this special issue. It has also been suggested that
autophagy plays a role in the initiation or progression of some
neurodegenerative diseases [20]. This suggestion originates from the
observed accumulation of autophagic vacuoles in neurons from
affected brain regions in a number of neurodegenerative diseases,
including Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob
disease, and many of the polyglutamine diseases [21–24]. This notion
has since been validated by experimental evidence and insights
provided by human genetics, as described below.
4. Neurodegeneration is frequently characterized by increased
frequency of autophagic vacuoles
Huntington's and Alzheimer's diseases are among the best-studied
examples where histopathology implicates autophagy as playing ation of UPS-like E1-E2-E3 cascades. In each case, an E1 enzyme activates a ubiquitin-like
ng enzyme, followed by an associationwith an E3 ligase that promotes association of the
vating enzyme, E2-conjugating enzyme, and an E3-ligase. (b) In the ﬁrst arm of the Atg
10, and is subsequently conjugated to Atg5. No E3-like protein has been identiﬁed in this
e Atg7, is transferred to the E2-like Atg3, and is conjugated to PE via the E3-like action of
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massive accumulation of autophagic vacuoles within large swellings
along dystrophic and degenerating neurites in neocortical and
hippocampal pyramidal neurons [21]. In Huntington's disease, affected
neurons show accumulation of huntingtin in cathepsin D positive
vacuoles [24]. cathepsin D is a lysosomal protease enriched in neuronal
tissues, suggesting that these are autolysosomes. However, the
observed increased frequency of autophagic vacuoles in disease brain
is ambiguous with respect to whether autophagy is induced or
whether autophagy ﬂux is impaired. Furthermore, autophagosomes
are frequently observed in dying neurons, where it is unclear whether
autophagy is operating as a futile cytoprotective response, whether
autophagy mediates cell death, or whether it is induced secondarily in
a cell already otherwise committed to dying. Insight into the role of
autophagy in neurodegeneration has been provided by studies
indicating that: 1) some neurodegenerative disease-related proteins
are degraded by autophagy, 2) impairment of autophagy promotes
neurodegeneration in animal models and several human neurodegen-
erative diseases, and 3) manipulation of autophagy modiﬁes pheno-
types in animal models of neurodegeneration.
5. Neurodegenerative disease-related proteins are degraded by
autophagy
That neurodegenerative disease-causing proteins are frequently
degraded by autophagy was demonstrated by a series of in vitro
studies which showed that pharmacological induction or inhibition of
macroautophagy alters the rate of turnover of a number of disease-
related proteins including polyglutamine-expanded proteins, poly-
alanine-expanded proteins, as well as wild type and mutant forms of
α-synuclein [25,26]. Moreover, ultrastructural analysis by immuno-
electron microscopy showed that in cell culture models, disease-
related proteins are delivered to autophagic vacuoles [27,28]. CMA has
also been found to contribute to the degradation of α-synuclein [29].
Collectively, these studies suggested that autophagy contributes to the
degradation of multiple disease proteins and the efﬁciency of this
pathway could relate to the onset or progression of disease. Of note,
there is evidence that many of these same disease-causing proteins
are also degraded by the UPS [30–32], suggesting that more than one
degradative routemay be available to them. In the case ofα-synuclein,
for example, Webb et al. concluded that soluble forms of the disease
protein are efﬁciently degraded by the UPS, while aggregated or
oligomeric α-synuclein require autophagy for clearance [26]. These
observations have led to the suggestion that autophagy provides an
alternate, compensatory route of degradation when clearance by the
UPS and CMA are compromised. The relative contribution of
autophagy and the UPS to degrading disease-related substrates, and
the relationship of this to the onset and progression of various
diseases, remains to be elucidated — and this may differ amongst
different diseases.
6. Impairment of autophagy promotes neurodegeneration
It is becoming increasingly evident that the autophagy-lysosomal
system is essential to neuronal homeostasis, and may in some settings
be neuroprotective. The consequences of impaired lysosome function,
for example, may be observed in cathepsin D knockout mice and
Drosophila melanogaster cathepsin D mutants which show neurode-
generation and associated accumulation of autophagosomes and
lysosomes [33–35]. The importance of autophagy to neuronal home-
ostasis is further illustrated by characterization of mice with
conditional knockout of Atg genes. These mice die prematurely with
extensive neurodegeneration and ubiquitin-positive pathology
[36,37]. On the basis of these observations one might predict that
impairment of autophagy could contribute to neurodegenerative
disease in humans. Indeed, primary lysosomal dysfunction ininherited congenital “lysosomal storage disorders” has long been
recognized to cause severe neurodegenerative phenotypes character-
ized pathologically by accumulations of lysosomes and autophagic
vacuoles [38]. For example, the neuronal ceroid lipofuscinoses (NCLs)
are a heterogeneous group of inherited, neurodegenerative disorders
with onset ranging from infancy to late adulthood that are caused by a
variety of defects in lysosomal function. Furthermore, a growing list of
adult-onset, familial neurological diseases have been linked to
mutations expected to have an impact on autophagy-lysosomal
function (reviewed in [38]), including Kufor-Rakeb syndrome (a
form of early-onset parkinsonism with dementia) [39], Charcot-
Marie-Tooth type 2B (CMT2B) [40], and distal-spinobulbar muscular
atrophy (distal-SBMA) [41]. Mutations in CLN3, a transmembrane
protein that localizes to the late endosomal/lysosomal membrane,
cause a form of NCL. CLN3-related neurodegeneration appears to be a
consequence of reduced autophagosome-lysosome fusion [42]. Muta-
tions in ATP13A2, which encodes a primarily neuronal lysosomal
ATPase, were recently found to cause Kufor-Rakeb syndrome
(previously designated PARK9). Disease-causing mutations in
ATP13A2 result in protein retention in the endoplasmic reticulum
and enhanced proteasomal degradation, suggesting that neurodegen-
eration could be caused by overwhelming the UPS and/or loss of
function in lysosomal protein degradation [39]. Mutations in Rab7
cause the dominantly inherited axonal neuropathy CMT2B. Rab7
participates in trafﬁcking autophagosomes and fusionwith lysosomes
and disease-causing mutations are predicted to impair this process
[43–45]. Mutations in p150/dynactin are responsible for the motor
neuron disease distal-SBMA. Microtubule-based vesicular trafﬁcking
is essential for delivery of autophagosomes to lysosomes and
subsequent fusion [46], and impaired dynein-mediated trafﬁcking is
associated with impaired autophagosome/lysosome fusion and
reduced protein turnover [47,48]. Thus, motor neuron loss in distal-
SBMA may result from impaired autophagosome trafﬁcking and/or
fusion with lysosomes. Indeed, a mouse model of distal-SBMA that
expresses mutant p150/dynactin is characterized by accumulation of
ubiquitin-positive aggregates and autophagic vacuoles in affected
neurons [49].
7. Manipulation of autophagy modiﬁes neurodegenerative
phenotypes in animal models
While deﬁciency in autophagy results in neurodegeneration, a
separate question concerns the role of autophagy in the context of
diseases initiated by mutations in genes unrelated to autophagic
function. To investigate this perspective, researchers have turned to
animal models of common neurodegenerative diseases that are
amenable to genetic and pharmacological manipulation of autophagy.
These studies have largely shown that reduced autophagy worsens
disease phenotypes whereas augmented autophagy provides beneﬁt,
leading to the conclusion that autophagy is cytoprotective. For
example, in a Drosophila model of X-linked spinobulbar muscular
atrophy (SBMA), a polyglutamine disease, degeneration was strongly
enhanced by genetic inhibition of autophagy [50]. Similarly, in
transgenic mice expressing amyloid precursor protein, a model of
Alzheimer's disease, genetic inhibition of autophagy by heterozygous
depletion of beclin-1 resulted in enhancement of neurodegeneration
[51]. In both of these studies it was determined that autophagy
deﬁciency results in greater accumulation of the offending, disease-
related protein [50,51], suggesting that autophagy was needed to
degrade cytotoxic proteins. This provided the rationale for investigat-
ing whether increasing autophagic activity might provide beneﬁt.
Pharmacological upregulation of autophagy can be accomplished
using the drug rapamycin, which works by inhibiting TOR (target of
rapamycin), a pleiotropic molecule that negatively regulates autop-
hagy, among other functions. Indeed, treatment with rapamycin
ameliorates the degenerative phenotype in a Drosophila model of
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disease [48,50,52]. In addition, inducing autophagy in an TOR-
independent manner using lithium [53] or trehalose [54–56] has
been shown to accelerate clearance of disease proteins in vitro [56]
and protect against neurodegeneration in mouse and Drosophila
models of Huntington's disease [53,54]. These exciting results have
opened the door to the possibility that pharmacological upregulation
of autophagy by rapamycin, lithium, trehalose, or a newer generation
of small molecules might be of therapeutic beneﬁt for patients with
neurodegenerative disease. Recently, high throughput screening
efforts have identiﬁed small molecule activators of autophagy. Some
of these compounds inhibit TOR and activate autophagy in a manner
analogous to rapamycin, but other compounds are TOR-independent
and reﬂect multiple points of potential therapeutic intervention [57].
There have been fewer efforts to manipulate UPS function for
therapeutic beneﬁt in neurodegenerative disease, but it was recently
shown that use of a proteasome activator enhanced survival in an in
vitro model of Huntington's disease [58], suggesting that augmenting
other routes of protein degradationmay also provide neuroprotection.
However, it should be pointed out that the relationship of
autophagy to the accumulation of disease protein may not always be
straightforward. There is evidence that in some cases cellular attempts
to degrade cytotoxic protein aggregates interfere with normal
autophagy function leading to lysosomal “indigestion” that ultimately
compromises cell function or viability. For example, α-synuclein is
degraded at least in part by CMA [29]. Mutations in α-synuclein that
are causative of familial Parkinson's disease are poorly transferred to
the lysosomal lumen and accumulate on the lysosomal surface,
resulting in blockade of receptor-mediated translocation. This results
in disrupting degradation of other CMA substrates [29,59]. With
respect to Alzheimer's disease, an even more complex story is
emerging. Several lines of evidence suggest that there is an
impairment of autophagy resulting from impaired autophagosome-
lysosome fusion combinedwith decreasing efﬁciency of the lysosomal
system [60]. These vacuolesmay further contribute to pathogenesis by
interfering with normal intracellular trafﬁcking and/or by leaking
undigested toxic contents into the cytosol, or more generally by
disrupting normal metabolic turnover required for neuronal home-
ostasis. Recent evidence suggests that the autophagic turnover of
amyloid beta precursor protein (APP) may underlie the generation of
toxic amyloid-β species [61]. Thus, the relationship of autophagy to
Alzheimer's disease progression is complex, with autophagy-related
production of toxic amyloid-β that culminates in impaired autophagy
and exacerbation of disease.
8. Links between UPS and autophagy
The UPS and autophagy were long viewed as independent, parallel
degradation systems with no point of intersection. This view was
initially challenged by the observation that monoubiquitination
operates as a key signal in endocytosis, a process important for
numerous cell functions including lysosomal biogenesis [62]. Subse-
quently, several lines of evidence have developed suggesting that the
UPS and autophagy are functionally interrelated catabolic processes
[50,63,64]. Speciﬁcally, these degradation systems share certain
substrates and regulatory molecules, and show coordinated and, in
some contexts, compensatory function. Thus, in contrast to the
traditional notion of the UPS and autophagy providing discrete routes
of degradation for short-lived and long-lived proteins, respectively, it
is increasingly clear that a substantial subset of proteins may be
degraded by either pathway. Short-lived proteins normally degraded
by the UPS can be selectively degraded by autophagy under certain
conditions [65,66], while longer-lived proteins can also be degraded
by the UPS [67]. The neuronal proteinα-synuclein, for example, can be
degraded by the UPS, macroautophagy and chaperone-mediated
autophagy [26,29]. Under conditions inwhich one degradation systemis compromised, enhanced degradation by an alternate pathway may
become critical to maintaining pools of amino acids for protein
synthesis and may protect against the accumulation of a toxic species.
As mentioned above, dramatic illustration of the interrelatedness of
the UPS and autophagy was provided by characterizations of mice
with conditional knockout of the essential autophagy genes Atg5 or
Atg7 in the central nervous system, which resulted in neurodegenera-
tion with accumulation of ubiquitin-positive pathology [36,37]. Given
that these mice showed no observable defect in UPS function, these
results suggest that some ubiquitin-tagged proteins may in fact
normally be degraded by autophagy. This model is consistent with an
older study showing that inactivation of the ubiquitin-activating
enzyme E1 leads to a defect in autolysosomal degradation and to an
absence of ubiquitin-positive proteins within lysosomes [68].
Further illustration of the relationship between the UPS and
autophagy can be found in a series of in vitro studies that examined
the behavior of cells following challenge to the UPS. When cultured
cells are challenged with excess misfolded protein that overwhelms
the UPS, or treated with proteasome inhibitors, ubiquitinated
misfolded proteins are actively transported to a cytoplasmic, juxta-
nuclear structure that has been termed an “aggresome” [69]. It has
been inferred that aggresome formation in vitro is a cytoprotective
response in cultured cells since their formation correlates inversely
with cell death, whereas interventions that block aggresome forma-
tion enhance cytotoxicity and slow the rate of turnover of misfolded
proteins [27,64,70–72]. While aggresomes superﬁcially resemble the
cytoplasmic inclusions present in some neurodegenerative diseases,
evidence of aggresome formation in vivo is lacking, and most
pathological inclusions found in neurodegenerative disease are clearly
not aggresomes. Nevertheless, studying the phenomenon of aggre-
some formation in vitro has provided insight into the cellular
management of misfolded proteins; for example, helping to identify
molecular machinery that protects cells frommisfolded protein stress.
It has now been established that clearance of misfolded proteins from
aggresomes is mediated at least in part by autophagy, implicating this
pathway as a compensatory mechanism for degrading misfolded
proteins when the proteasome is impaired [27,64,71,73].
In addition to aggresome formation, impairment of the UPS in vitro
has been found to induce autophagy [63,64]. This is observed, for
example, in HeLa cells after prolonged proteasomal inhibition as
evidenced by redistribution of LC3 into numerous puncta (Fig. 3a–c)
and the accumulation of autophagic vacuoles based upon ultrastruc-
tural evaluation (Fig. 3d–g). Similar induction of autophagy is observed
in response to genetic impairment of the proteasome inDrosophila [50].
The role of autophagy induction in the setting of UPS impairment
appears to be cytoprotective since degenerative phenotypes associated
with proteasome impairment are enhanced in an autophagy-deﬁcient
background (Fig. 4a–c), whereas this degeneration is suppressed when
autophagy is induced with the TOR-inhibitor rapamycin (Fig. 3d).
Similar results have recently been observed in vitro using the
proteasome inhibitor lactacystin, as pre-treatment with rapamycin
attenuates lactacystin-induced apoptosis and reduces lactacystin-
induced ubiquitinated protein aggregation [74].
Although the mechanismwhereby autophagy and UPS function are
coordinated is little understood, several regulators have emerged as
important players in mediating this crosstalk, including histone
deacetylase 6 (HDAC6) [50,64,75], p62/sequestosome 1 (p62) [76],
and the FYVE-domain containing protein Alfy [77]; notably, these
proteins have all been found to regulate or be essential for aggresome
formation. HDAC6 is a cytoplasmic microtubule-associated deacetylase
whose targets includeα-tubulin, Hsp90, and cortactin.HDAC6 interacts
with polyubiquitinated proteins through a highly conserved Zn-ﬁnger
ubiquitin-binding domain, and also interacts with dynein motors,
suggesting that the molecule may provide a physical link between
ubiquitinated cargo and transport machinery [70]. HDAC6 activity
appears to be important for trafﬁcking ubiquitinated proteins and
Fig. 3. Proteasome impairment leads to upregulation of autophagic activity. (a) HeLa cells that stably express the UPS reporter UbG76V-GFP were treated with the irreversible
proteasome inhibitor epoximicin for 72 h andmonitored for cell death. Increasing levels of the GFP substrate indicate impaired UPS function. Note the 24 h time point used in (b–g) is
within the window during which proteasome function is impaired, but the cells remain viable. (b, c) Images of LC3 staining (red) and DAPI (blue) show accumulation of LC3 puncta in
epoximicin-treated cells. (d, e) Transmission electron microscopy images of cells reveal autophagic structures and prominent vacuolization in epoximicin-treated cells. (f, g)
Increased magniﬁcation of structures in (e) reveal multi-membraned structures consistent with autophagic activity.
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coordinates delivery of substrates to autophagic machinery [64,70,78].
In Drosophila, HDAC6 overexpression was found to suppress degenera-
tion associated with impaired UPS activity and also suppressed
degeneration caused by toxic polyglutamine expression. In both cases,
this rescue byHDAC6was found to be autophagy dependent, consistent
with a role for HDAC6 in linking the UPS and compensatory autophagy
[50]. HDAC6 activity was also reported to regulate chaperone expres-
sion in response to heat shock bydeacetylatingHsp90 leading to release
and activation of the transcription factor HSF-1 [79].
p62 is another cytosolic protein whose structure suggests a
function as an adaptor molecule linking ubiquitinated proteins to
autophagic machinery. The C-terminal portion of p62 harbors both a
ubiquitin-associated (UBA) domain which interacts non-covalently
with ubiquitinated proteins [80,81] as well as an LC3-interacting
region (LIR) [82]. Cellular stresses such as polyglutamine expression,
proteasome impairment, oxidative stress, and increased misfolded
protein burden activate transcription and translation of p62, suggest-
ing that it functions broadly in stress situations [83,84]. p62 localizes to
a variety of ubiquitin-positive neuropathological inclusions including
Lewy bodies in Parkinson's disease, neuroﬁbrillary tangles in tauo-
pathies, polyglutamine-expanded huntingtin aggregates in Hunting-
ton's disease, and aggregates of mutant SOD1 in familial amyotrophic
lateral sclerosis [85–87]. A role for p62 in protecting against misfolded
protein stress is supported by the observation that RNAi-mediated
knockdown of p62 exacerbates polyglutamine toxicity in vitro and
diminishes the formation of ubiquitin-positive inclusions in response
tomisfolded protein stress [76] while reducing the ability of LC3 to co-
precipitate ubiquitinatedproteins [82]. Very recently, p62was found tocontain an LC3 recognition sequence that, when mutated, resulted in
ubiquitin-and p62-positive inclusion formation [88]. Thus, it has been
suggested that p62 provides a key link between autophagyand theUPS
by facilitating autophagic degradation of ubiquitinated proteins. As
predicted by this model, p62 null mice fail to form ubiquitin-positive
protein aggregates in response to misfolded protein stress [89] and
show age-related neurodegeneration [90]. Consistent results were
obtained in studies of Drosophila deﬁcient in Ref(2)p, the Drosophila
homologue of p62 [91]. Recent models propose that p62 and HDAC6
function analogously to facilitate autophagic degradation of proteins
that display speciﬁc polyubiquitin topology. Speciﬁcally, it is suggested
that K63-linked polyubiquitin chains recruit p62 andHDAC6 providing
a signal for autophagic degradation [92,93].
Alfy (autophagy-linked FYVE protein) is a third possible molecular
link between autophagy and the UPS. Alfy is a member of the FYVE-
domain family of proteins. In cells that are exposed to stressors such as
starvation or UPS inhibition, Alfy relocalizes from the nuclear envelope
to ﬁlamentous cytoplasmic structures that are near autophagic
membranes and ubiquitinated protein inclusions, as well as within
autophagosomes [77]. Mutations in blue cheese, the Drosophila
homology of human Alfy, lead to reduced longevity and the
accumulation of ubiquitinated neural aggregates, suggesting that its
role in autophagic degradation may be involved in the clearance of
ubiquitin aggregates [77,94].
9. Summary and unresolved questions
The last few years have led to substantial insight into the
relationship between autophagy and the UPS. It has become apparent
Fig. 4. A Drosophila model of proteasome impairment is modiﬁed by manipulation of autophagic activity. (a, b) The temperature-sensitive DTS7 mutant shows a normal eye
phenotype at the permissive temperature of 22 °C and a signiﬁcant degenerative phenotype at the restrictive temperature of 28 °C. (c) RNAi knockdown of the autophagy gene atg12
results in an enhancement of the DTS7 degenerative phenotype, suggesting that the autophagic activity that is induced in response to proteasome impairment is compensatory. (d)
Treatment of DTS7 ﬂies with rapamycin suppresses the degenerative phenotype, demonstrating that induction of autophagy can compensate for impaired proteasome function.
Adapted from [50].
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regulation of these catabolic pathways by UBLmodiﬁcation, leading to
the suggestion that they evolved from a common biological origin
[95]. Further, it has become evident that the function of autophagy
and the UPS are coordinated. For example, impairment of the UPS
results in upregulation of autophagy ([50,64] and Fig. 3), and in some
contexts this upregulation of autophagy can compensate for impaired
UPS function [50,74]. However, it is not known whether this
compensatory relationship is reciprocal, as few reagents exist to
upregulate the UPS. One study found that upregulation of UPS may
afford neuroprotection from toxicity caused by disease proteins,
though the authors did not examine the effects of UPS upregulation in
autophagy-deﬁcient cells [58]. The mechanism and the molecular
players that regulate the relationship between autophagy and the UPS
are beginning to be elucidated and, perhaps not surprisingly,
recognition of UBL modiﬁcation is emerging as a consistent theme.
CMA is also clearly involved in the coordinated functioning of
proteolytic pathways. CMA can selectively degrade some subunits of
the proteasome, highlighting a relationship between CMA and the UPS
[96]. In addition, acute blockage of CMA results in short-term
impairment of both the UPS and macroautophagy, followed by a
recovery of these catabolic systems as CMA blockade persists [97].
Chronic blockage of CMA results in constitutive activation of
macroautophagy, which appears to be compensatory [59]. These
interrelationships suggest a model in which the preferred route of
degradation for a particular substrate may be linked to which system
is most capable of efﬁciently degrading it.
While much has been revealed in recent years, substantial
questions remain. Most notable, it is largely unknown how the
decision is made between degradative routes for any particular
protein substrate when more than one pathway is available. HDAC6,
p62, and Alfy have been implicated in directing ubiquitinated
proteins for autophagic degradation, but the mechanisms whereby
these proteins identify their targets and inﬂuence their degradation
are still unknown. Tantalizing recent evidence suggests that
different classes of substrates may be identiﬁed by polyubiquitin
chains of differing topology, providing the signal for degradation by
one proteolytic system or the other [93, 98]. More speciﬁcally, it has
been suggested that polyubiquitin chains with K48-linked chainsare primarily degraded by the UPS, whereas those with K63-linked
chains are directed to autophagy. Indeed, one might envision a
“ubiquitin code” that translates into interaction with speciﬁc
ubiquitin binding proteins, including HDAC6, Alfy, p62 or other
members of the UBA family [99], which may in turn determine the
fate of the substrate. However, experimental limitations in distin-
guishing between K48-, K63-and mixed-linkage ubiquitin chains
must be overcome in order to answer this question effectively, and
many of these relationships remain largely unexplored. This concept
of different classes of substrates that are destined for degradation
by differing pathways is consistent with one recent report in which
disease-associated proteins were found to partition into two distinct
intracellular compartments, with soluble ubiquitinated proteins
accumulating in a proteasome-rich juxtanuclear region, and inso-
luble aggregated proteins accumulating in perivacuolar inclusions
that colocalize with Atg8 [100]. It would be interesting to determine
whether these proteins could be distinguished by differing UBL
modiﬁcations.
The mechanism by which upregulation of autophagy mitigates
neurotoxicity associated with UPS impairment is also unresolved. It is
unlikely that autophagy is able to compensate for the role of the UPS
in ﬁne-tuning the steady-state levels of short-lived regulatory
proteins. More likely, augmentation of autophagy is neuroprotective
by 1) maintaining the overall rate of catabolism, “freeing” amino acids
that would otherwise lie useless in aggregated, nonfunctioning
proteins, 2) eliminating speciﬁc protein substrates that would
otherwise accumulate, aggregate and acquire toxic properties, or 3)
a combination of these.
Further illumination of the relationship between the UPS,
autophagy and the relationship to human disease is vitally important
and could lead to harnessing intrinsic catabolic pathways for
therapeutic beneﬁt.
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